Patient P-03201

Synthetic patientONX-7 · Day 139 · 75+ · M · baseline S15Steering view · 3D Open companion preview

Therapy response

Improving

Tolerance

Deteriorating

GI state

Stable

Inflammatory state

Deteriorating

Nutritional resilience

Declining

Discontinuation risk

46%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 ONX-7 started — Baseline state S15
Day 102 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 102 GI-04 recommended — GI Support Protocol GI-04
Day 103 Patient accepted — Started GI-04 in the companion
Day 111 GI symptom burden −12% vs expected — GI Support Protocol GI-04
Day 117 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 102.

Primary contributors, last 14 days

Treatment adherence-13
Toxicity+11
Inflammatory activity+8
Nutritional resilience-6

What helped?

GI Support Protocol GI-04Day 102
Result: symptom burden −12%

LIFE OS recommendation

Dosing / Timing Recommendation DT-01

62%

probability of meaningful tolerance improvement

284 similar trajectories
82% showed improvement
median effect visible after 5 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Energy level

Daily log

3.6/10

stable · -0.1 vs previous 14 d

Stress level

Daily log

5.1/10

stable · +0.2 vs previous 14 d

Pessimism score

Daily log

3.6/10

stable · +0.0 vs previous 14 d

Sleep quality

Wearable

27.4/100

worsening · -2.2 vs previous 14 d

Libido

Daily log

3.5/10

worsening · -0.4 vs previous 14 d

HRV

Wearable

52.8 ms

stable · -1.5 vs previous 14 d

Toxicity

Blood

35.9/100

worsening · +2.9 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards restoration · 49 from the failing basin, 47 from restoration.

Would help

DT-01 Dosing / Timing Recommendation
82% improved among 11 similar · onset 5 d · confidence 61%
NP-02 Dietary Support Protocol
57% improved among 14 similar · onset 10 d · confidence 61%
HY-01 Hydration Protocol
57% improved among 7 similar · onset 4 d · confidence 61%
More protein
GI -5.9 next day on high-intake days · n 13

Would not help

AD-05 Adherence Support
only 25% improved among 8 similar
Keep histamine low
GI +6.4 next day on high-intake days · n 18

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Histamine load
+6.4detractor · 95%
Protein
-5.9supporter · 95%
Caffeine
+1.5no signal · 28%
Alcohol
+1.4no signal · 25%
Dietary fat load
-0.6no signal · 15%
Lactose
-0.6no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 51 and rising
- WearableSleep 5.9 h, below personal baseline
Butyrate / short-chain fatty acid production ↓45
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Autonomic recovery ↑40
- Wearable2,631 steps/day
- WearableShort sleep window
Drug metabolism and exposure ↑35
- DNADPYD *2A → slower clearance
Inflammatory signalling ↑25
- BloodInflammatory load index 54

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
DPYD *2A heterozygous
Slower drug clearance
CYP2D6 Normal metabolizer
Expected exposure

Microbiome

Shannon diversity 2.9 · butyrate capacity 45/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisNormal
Bifidobacterium longumNormal
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 50 ms
Sleep: 6.3 h
Steps: 2,742
Resting HR: 70 bpm

Daily log: GI score 51, nutritional resilience 42, adherence 67.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-03465	46%	S17	CR-01	improved	65
P-03166	44%	S20	CR-01	improved	62
P-03382	41%	S01	GI-04	improved	56
P-03146	39%	S14	GI-04	improved	53
P-03225	39%	S19	GI-04	improved	50
P-03357	37%	S02	CR-01	improved	50
P-03070	36%	S14	GI-04	improved	51
P-03279	35%	S14	GI-04	improved	57
P-03031	34%	S16	CR-01	improved	49
P-03099	34%	S17	CR-01	improved	55
P-03110	34%	S15	GI-04	improved	52
P-03123	34%	S14	GI-04	improved	50